The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
Open accessAbstract
Ketamine is an open channel blocker of ionotropic glutamatergic N -Methyl- D -Aspartate (NMDA) receptors. The discovery of its rapid antidepressant effects in patients with depression and treatment-resistant depression fostered novel effective treatments for mood disorders. This discovery not only provided new insight into the neurobiology of mood disorders but also uncovered fundamental synaptic plasticity mechanisms that underlie its treatment. In this review, we discuss key clinical aspects of ketamine’s effect as a rapidly acting antidepressant, synaptic and circuit mechanisms underlying its action, as well as how these novel perspectives in clinical practice and synapse biology form a road map for future studies aimed at more effective treatments for neuropsychiatric disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Importantly, this mechanism reframes NMDAR antagonism as permissive rather than suppressive, with intact upstream NMDA signaling required to enable AMPA driven plasticity [20,44,45,51].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [20]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postsynaptic activity triggers BDNF release and TrkB receptor activation, which in turn engages mechanistic target of rapamycin complex 1 (mTORC1) dependent translational programs supporting dendritic spine growth and synaptic strengthening [20,42,48,49,50].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These cascades converge to produce long-term potentiation (LTP) like synaptic potentiation across corticolimbic circuits within hours, mirroring the temporal profile of ketamine’s antidepressant effects [20,33,48].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The result is a brief but robust glutamate surge that drives enhanced α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) throughput and calcium influx, including through calcium permeable AMPA channels [20,42,47].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sustained antidepressant benefit requires presynaptic mechanisms that preserve release fidelity after postsynaptic remodeling.”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [20]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
(2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00395-3 · Cited by 6,481 · cited 1×
“Despite over 60 years of antidepressant development, mood disorders remain among the most disabling medical conditions in the world and they are associated with shortening of life expectancy by up to 10 years [5, 6].”
BackgroundRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“…initial antidepressant, modest incremental bene fi ts were seen with subsequent treatments, approximately one-third of patients remained unremitted after four treatments, and the one-year relapse rate among patients with treatment-resistant symptoms (Steps 3 and 4) was approximately 75% [7, 8].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“The initial pilot study used the previously ketamine infusion strategy to conduct the fi rst randomized, placebo-controlled test of ketamine response in depression [26].”
MethodSelf-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 2×
“However, none of these studies predicted the distinctively rapid and robust antidepressant effects of a single ketamine dose in depressed patients observed in the initial pilot study, nor the ef fi cacy in treatment-resistant symptoms of depression, bipolar disorder [30] or suicide ideation [31].”
BackgroundResultA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375 · cited 1×
“Earlier studies on the mechanisms of action of classical antidepressant in preclinical models established a strong causal link of BDNF and subsequent signaling via TrkB receptors as a key mediator of antidepressant action [99, 100].”
BackgroundSelf-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 3×
“The resulting increase in glutamatergic activity produces downstream activation of mammalian target of rapamycin (mTOR) function to increase dendritic spine formation and produce the rapid and sustained antidepressant effects [87, 90] (see Fig.”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 10×
“Moreover, extensive studies have also demonstrated that homeostatic synaptic plasticity elicited by NMDA receptor block by ketamine occurs rapidly within hours consistent with the time course of ketamine action [60, 95, 97].”
BackgroundInfluentialSelf-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Research works printed but not linked: 2
- Kuhn R. The discovery of the tricyclic antidepressants and the history of their use in the early years. In: Ban TA, Ray OS, editors. A History of the CINP. Brentwood: Brentwood press; 1996. p. 425–35.
- Berman RM, Krystal JH, Charney DS. Mechanism of action of antidepressants: monoamine hypotheses and beyond. In: Watson SJ, editor. Biology of Schizophrenia and Affective Disorders. Washington, D.C.: American psychiatric press, Inc; 1996. p. 295–368.
Cited by
Nicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
“Preclinical studies have revealed that the rapid antidepressant effect of ketamine is associated with the restoration of dysfunctional glutamatergic transmission and promotion of neuroplasticity in corticolimbic areas [150,173–175].”
BackgroundThe neuroplastic brain: current breakthroughs and emerging frontiers
Gazerani, P. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149643 · Cited by 174
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 104
“It is among the leading causes of morbidity and mortality [3], and the past 60 years have been devoted to extensive research, investigating its etiological mechanisms and evidence-based treatment strategies [4, 5].”
BackgroundTherapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
“Mechanisms of ketamine for psychiatric indications are extensively reviewed elsewhere in this issue [35], but we will compare the effects of psychedelics and entactogens to ketamine throughout this review when appropriate.”
BackgroundKawczak, P., Feszak, I. J., & Bączek, T. (2024) · Biomedicines · doi:10.3390/biomedicines12102283 · Cited by 73
“Identifying compounds that specifically target homeostatic plasticity could represent a promising new therapeutic strategy [53].”
Background
Metadata
- Authors
- Krystal, J. H., Kavalali, E. T., & Monteggia, L. M.
- Affiliations
- Yale University (US)
- Vanderbilt University (US)
- Corresponding author
- Monteggia, Lisa M.
- Venue
- Neuropsychopharmacology
- Published
- 2023-07-24
- Volume
- 49
- Issue
- 1
- Pages
- 41-50
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- PMC
- PMC10700627
- OpenAlex
- W4385196900
- Cited by
- 262
- References
- 132
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 60 · 2023: 5
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH070727, MH081060, MH066198)
- Department of Veterans Affairs | Office of Academic Affiliations, Department of Veterans Affairs (National Center for PTSD)
- Yale | YSM | Yale Center for Clinical Investigation, Yale School of Medicine (2UL1TR001863)
- U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (2P50AA012870)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, treatment-resistant depression, NMDA receptor antagonism, synaptic plasticity, synaptic signaling, mood disorders, neuropsychiatric disorders, antidepressant mechanism
- MeSH terms
- Antidepressive Agents, Depression, Humans, Ketamine, Synapses, Receptors, N-Methyl-D-Aspartate, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. https://app.cochat.ai/papers/10.1038/s41386-023-01629-w
- The paper
- Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01629-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.